

The results will be presented in a poster session, poster board # LBP38.31) and in an afternoon Hot Topics session, poster board # (morning Hot Topics session). In addition to clinical data, a poster on the neuroprotective effects of NLX-112 in a mouse model of PD will be presented on Thursday, July 6, 2023 (poster board #P02.06).

Neurolix is a privately-held biopharmaceutical company focused on the discovery and development of novel drugs for treatment of central nervous system disorders including movement disorders, autism spectrum disorders, depression and pain. Neurolix has built a platform of serotonin 5-HT_{1A} receptor 'biased agonists' which more precisely target specific brain regions.

NLX-112 is an exceptionally selective 5-HT_{1A} receptor full agonist that has previously shown favorable safety and tolerance in over 600 subjects during Ph1 and Ph2 trials for indications other than LID, but had never been administered to PwP. The recent study (ClinicalTrials.gov ID: [NCT05148884](https://clinicaltrials.gov/ct2/show/study/NCT05148884)), which was supported by Parkinson's UK (grant DYS-20-02) and The Michael J. Fox Foundation (grant MJFF- 019508), investigated the effects of NLX-112 in PwP with troubling LID. Analysis of safety, tolerability and efficacy measures, including both LID and parkinsonism will be disclosed at the WPC meeting.

NLX-112 is also under study as a potential treatment for other movement disorders. Other drugs in the Neurolix pipeline are NLX-101 (phase 1) for autism spectrum disorders and NLX-204 (preclinical) for depression and pain.

For more information, contact Pim Cerutti, Head of US & EU Operations, Liberi Group Life Science Business Development & Strategy

PIM CERUTTI
LIBERI GROUP
pimcerutti@LiberiGroup.com

This press release can be viewed online at: <https://www.einpresswire.com/article/640520098>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.